Puma Biotechnology Inc (NASDAQ:PBYI) Shares Bought by Virginia Retirement Systems ET AL

Virginia Retirement Systems ET AL boosted its stake in Puma Biotechnology Inc (NASDAQ:PBYI) by 121.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,200 shares of the biopharmaceutical company’s stock after acquiring an additional 6,700 shares during the period. Virginia Retirement Systems ET AL’s holdings in Puma Biotechnology were worth $1,461,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of PBYI. Strs Ohio purchased a new position in shares of Puma Biotechnology in the second quarter worth about $122,000. Cubist Systematic Strategies LLC purchased a new position in Puma Biotechnology during the second quarter valued at approximately $146,000. Kazazian Asset Management LLC purchased a new position in Puma Biotechnology during the second quarter valued at approximately $209,000. Teacher Retirement System of Texas purchased a new position in Puma Biotechnology in the 2nd quarter worth approximately $211,000. Finally, Ameritas Investment Partners Inc. grew its stake in Puma Biotechnology by 5.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 140 shares in the last quarter. Hedge funds and other institutional investors own 96.00% of the company’s stock.

Puma Biotechnology Inc (PBYI) traded down $0.95 on Friday, reaching $98.85. 531,228 shares of the company’s stock traded hands, compared to its average volume of 658,385. The company has a market cap of $3,745.45, a PE ratio of -12.08 and a beta of 0.73. Puma Biotechnology Inc has a 1-year low of $28.35 and a 1-year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.50) by $0.43. Puma Biotechnology had a negative net margin of 1,270.04% and a negative return on equity of 310.69%. The firm had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $3.78 million. During the same quarter in the prior year, the business earned ($1.11) EPS. sell-side analysts anticipate that Puma Biotechnology Inc will post -8.19 earnings per share for the current year.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 21.10% of the stock is currently owned by company insiders.

A number of equities analysts have commented on the stock. Royal Bank of Canada cut their price target on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. They noted that the move was a valuation call. Citigroup restated a “buy” rating and issued a $156.00 price objective (up from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. Leerink Swann boosted their price objective on shares of Puma Biotechnology to $140.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Bank of America restated a “buy” rating and issued a $135.00 price objective (up from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Finally, BidaskClub upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $130.67.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2017/12/30/virginia-retirement-systems-et-al-has-1-46-million-holdings-in-puma-biotechnology-inc-pbyi.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply